SCHEMBL163221

SCHEMBL163221

C[C@@](N)(Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.47
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44
EGFR P00533 1/20 0.44
CYP1A2 P05177 1/20 0.44
FYN P06241 1/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
APEX1 P27695 1/20 0.44
ADRA1A P35348 1/20 0.44
PTGS2 P35354 1/20 0.44
MTOR P42345 1/20 0.44
RECQL P46063 1/20 0.44
CASP6 P55212 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL59406 1.00 BLM (0.47) BLMALDH1A1KDM4EMEN1USP2
SCHEMBL59405 1.00 BLM (0.47) BLMALDH1A1KDM4EMEN1USP2
Hydrochloric Acid SCHEMBL2808246 0.98 BLM (0.46) BLMALDH1A1KDM4EMEN1USP2
Hydrochloric Acid SCHEMBL28827254 0.98 BLM (0.46) BLMALDH1A1KDM4EMEN1USP2
Hydrochloric Acid SCHEMBL14832457 0.98 BLM (0.46) BLMALDH1A1KDM4EMEN1USP2
SCHEMBL28455493 0.87 BLM (0.33) BLMALDH1A1KDM4EMEN1USP2
SCHEMBL13702468 0.87 BLM (0.33) BLMALDH1A1KDM4EMEN1USP2
SCHEMBL1331226 0.83 BLM (0.32) BLMSMN1; SMN2HIF1A
SCHEMBL3510446 0.83 BLM (0.32) BLMSMN1; SMN2HIF1A
SCHEMBL2786983 0.83 BRS3 (0.32) BLMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1817 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215895-A1 Therapeutic and carrier molecules PEPLIN BIOLIPIDS PTY LTD (AU) 2009-08-27 US claimed
EP-1718602-A4 THERAPEUTIC AND CARRIER MOLECULES PEPLIN BIOLIPIDS PTY LTD (AU) 2007-12-12 EP claimed
US-7256172-B1 Method of treatment and agents useful for same THE UNIVERSITY OF MELBOURNE (AU) 2007-08-14 US claimed
EP-1718602-A1 THERAPEUTIC AND CARRIER MOLECULES Peplin Biolipids Pty Ltd. (AU) 2006-11-08 EP claimed
US-7070969-B1 Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis THE UNIVERSITY OF QUEENSLAND (AU) 2006-07-04 US claimed
WO-2005073164-A1 THERAPEUTIC AND CARRIER MOLECULES PEPLIN BIOLIPIDS PTY LTD (AU) 2005-08-11 WO claimed
CN-122094704-A Formulations for oral administration of active agents comprising a combination of acid-neutralizing polymer and non-polymeric material 2026-05-26 CN disclosed
WO-2026085582-A1 PROTEIN CAGES THE UNIVERSITY OF SYDNEY (AU) 2026-04-30 WO disclosed
EP-4627079-A2 THERMOSTABLE BINDING SCAFFOLDS Nectagen, Inc. (US) 2025-10-08 EP disclosed
CN-120202191-A Inhibitors of prostate specific membrane antigen and uses thereof 上海先通生物科技有限公司 2025-06-24 CN disclosed
EP-4551563-A2 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS, INC. (US) 2025-05-14 EP disclosed
WO-2025091087-A1 BISPECIFIC PROTEINS MONASH UNIVERSITY (AU) 2025-05-08 WO disclosed
CN-119816487-A FC conjugates comprising CD73 inhibitors and uses thereof 奇达拉治疗公司 2025-04-11 CN disclosed
WO-1997005257-A1 PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1997-02-13 WO disclosed
WO-1997004091-A1 NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-02-06 WO disclosed
EP-0745092-A1 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1996-12-04 EP disclosed
EP-0672049-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1995-09-20 EP disclosed
WO-1994028014-A2 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1994-12-08 WO disclosed
WO-1994011388-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1994-05-26 WO disclosed
WO-1994003483-A1 ENDOTHELIN RECEPTOR-BINDING COMPOUNDS CHIRON CORPORATION (US) 1994-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215895-A1 Therapeutic and carrier molecules PHKG1, PHKG2, DGKB BLM 3727/4885ALDH1A1 3631/4885KDM4E 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.